TigerGPT Answer: 【Forecast Data】
For Pfizer (PFE) this quarter, the financial forecast data is as follows:
- Earnings Per Share (EPS): $0.52
- Total Revenue: $14,008,235,290
- EBIT: $3,756,719,500
Compared to the same period last year:
- EPS has decreased by 57.72% (from $1.23)
- Total Revenue has decreased by 23.39% (from $18,282,000,000)
- EBIT has decreased by 51.52% (from $7,751,000,000)
The significant decline in EPS, revenue, and EBIT suggests that Pfizer may be facing challenges such as reduced demand for certain products, increased competition, or other operational headwinds.
【Quarterly Important News】
Key news over the past quarter includes:
- Pfizer and BioNTech's stock prices fell due to a lawsuit filed by GlaxoSmithKline, alleging infringement of mRNA vaccine technology patents.
- German Chancellor Olaf Scholz pledged support for the pharmaceutical industry, which could create a favorable environment for Pfizer's operations in Germany.
- The market is closely watching any changes in Pfizer's 2024 forecast, especially regarding COVID-19 vaccine and antiviral treatment Paxlovid.
These events could impact Pfizer's financial performance and future development, with the lawsuit potentially affecting profits and the German government's support possibly aiding future investments.
【Forecast Viewpoints】
Wall Street analysts project a decline in Pfizer's quarterly earnings and revenue. There has been a downward revision in consensus EPS estimates, indicating analysts' reconsideration of their initial forecasts. Here are the viewpoints from relevant articles:
- Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics: Read Article
- Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for: Read Article
【Stock Trend Analysis】
Pfizer's stock price has decreased by 3.61% over the past quarter. The latest price is $25.4 (USD), with a support level at $27.19 and a resistance level at $25.36. Analysts have a mixed view with 3 recommendations, 7 buys, and 16 holds. The mean target price is $31.1, with a low of $26.0 and a high of $45.0. The stock is currently trading below the mean target price, suggesting it may be undervalued.
【Options Large Order Analysis】
The options large orders show a mix of buy and sell orders for calls, indicating a bullish sentiment, while there is also a significant sell order for puts, which could suggest some bearish sentiment. The financial report could exceed expectations if the bullish sentiment from call options outweighs the bearish sentiment from put options.
【Analyst Ratings and Target Price Forecast】
With the stock trading below the mean target price and a mix of analyst ratings, Pfizer may be considered undervalued. If the financial report is better than expected, the stock price could move towards the target prices.
【Comprehensive Conclusion】
Pfizer is facing a challenging quarter with significant declines in forecasted EPS, revenue, and EBIT. The stock price trend and analyst ratings suggest the stock may be undervalued. The mixed options large orders indicate uncertainty, but there is a possibility of the financial report exceeding expectations if the bullish sentiment prevails.
Disclaimer: The above content is generated by the AI robot TigerGPT and does not represent any personal views. The content is for reference only and does not constitute any investment advice.
Comments